In general
section 9604(i) of this titleThe Centers for Disease Control and Prevention (referred to in this section as the “CDC”) shall be headed by the Director of the Centers for Disease Control and Prevention (referred to in this section as the “Director”), who shall be appointed by the President, by and with the advice and consent of the Senate. Such individual shall also serve as the Administrator of the Agency for Toxic Substances and Disease Registry consistent with . The Director shall perform functions provided for in subsection (b) and such other functions as the Secretary may prescribe.
Functions
Strategic plan
In general
Not later than 1 year after , and at least every 4 years thereafter, the Director shall develop and submit to the Committee on Health, Education, Labor, and Pensions and the Committee on Appropriations of the Senate and the Committee on Energy and Commerce and the Committee on Appropriations of the House of Representatives, and post on the website of the CDC, a coordinated strategy to provide strategic direction and facilitate collaboration across the centers, institutes, and offices within the CDC. Such strategy shall be known as the “CDC Strategic Plan”.
Requirements
Use of plans
Strategic plans developed and updated by the centers, institutes, and offices of the CDC shall be prepared regularly and in such a manner that such plans will be informed by the CDC Strategic Plan developed and updated under this subsection.
Appearances before Congress
In general
Clarifications
Waiver authority
The Chair of the Committee on Health, Education, Labor, and Pensions of the Senate or the Chair of the Committee on Energy and Commerce of the House of Representatives may waive the requirements of paragraph (1) for the applicable fiscal year with respect to the applicable Committee.
Scope of requirements
The requirements of this subsection shall not be construed to impact the appearance of other Federal officials or the Director at hearings of either Committee described in paragraph (1) at other times and for purposes other than the times and purposes described in paragraph (1).
Closed hearings
Information that is not appropriate for disclosure during an open hearing under paragraph (1) in order to protect national security may instead be discussed in a closed hearing that immediately follows the open hearing.
Other transactions
In general
In carrying out activities of the Centers for Disease Control and Prevention, the Director may enter into transactions other than a contract, grant, or cooperative agreement for purposes of infectious disease research, biosurveillance, infectious disease modeling, and public health preparedness and response.
Written determination
With respect to a project that is expected to cost the Centers for Disease Control and Prevention more than $40,000,000, the Director may exercise the authority under paragraph (1) only upon a written determination by the Assistant Secretary for Financial Resources of the Department of Health and Human Services, that the use of such authority is essential to promoting the success of the project. The authority of the Assistant Secretary for Financial Resources under this paragraph may not be delegated.
Guidelines
The Director, in consultation with the Secretary, shall establish guidelines regarding the use of the authority under paragraph (1). Such guidelines shall include auditing requirements.
July 1, 1944, ch. 373Pub. L. 117–328, div. FF, title II, § 2101(a)136 Stat. 5706(, title III, § 305, as added , , .)
Editorial Notes
References in Text
Section 9604(i) of this titlesection 104(i) of Pub. L. 96–510, referred to in subsec. (a), was in the original “section 104(i) of the Comprehensive Environmental Response, Compensation, and Liability Act”, and was translated as reading “section 104(i) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980”, meaning , to reflect the probable intent of Congress.
Prior Provisions
act July 1, 1944, ch. 373, title III, § 305July 3, 1956, ch. 510, § 370 Stat. 490Pub. L. 91–515, title II, § 21084 Stat. 1303Pub. L. 93–45, title I, § 10387 Stat. 91Pub. L. 93–353, title I, § 10488 Stat. 363Pub. L. 94–460, title III, § 30190 Stat. 1960Pub. L. 95–623, § 492 Stat. 3445Pub. L. 97–35, title IX, § 919(a)(1)95 Stat. 565Pub. L. 98–55198 Stat. 2817Pub. L. 99–117, § 699 Stat. 492Pub. L. 99–660, title III, § 311(b)(2)100 Stat. 3779Pub. L. 100–177, title I101 Stat. 987Pub. L. 100–607, title II, § 204(1)102 Stat. 3079Pub. L. 100–690, title II, § 2620(b)(3)102 Stat. 4244Pub. L. 101–93, § 5(e)(3)103 Stat. 612Pub. L. 101–239, title VI, § 6103(d)(1)(A)103 Stat. 2205A prior section 242c, , as added , ; amended , , ; , , ; , , ; , , ; , , ; , , (2)(A), (3), (b)(1), (c), (d), , 566; , , §§ 5(a), (b), 6, , 2819, 2820; , , ; , , ; , , §§ 101, 102, ; , , ; , , ; , , , related to National Center for Health Services Research and Health Care Technology Assessment, prior to repeal by , , .
Statutory Notes and Related Subsidiaries
Effective Date
Pub. L. 117–328, div. FF, title II, § 2101(b)136 Stat. 5709